ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

ProShare Advisors LLC boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 35.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,549 shares of the company’s stock after acquiring an additional 2,764 shares during the period. ProShare Advisors LLC’s holdings in Keros Therapeutics were worth $167,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KROS. Braidwell LP boosted its holdings in Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock worth $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Lynx1 Capital Management LP bought a new position in Keros Therapeutics in the fourth quarter worth approximately $8,612,000. Millennium Management LLC boosted its holdings in Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock worth $13,901,000 after acquiring an additional 305,169 shares in the last quarter. Boxer Capital Management LLC bought a new position in Keros Therapeutics in the fourth quarter worth approximately $3,958,000. Finally, Integral Health Asset Management LLC boosted its holdings in Keros Therapeutics by 125.0% in the fourth quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company’s stock worth $7,124,000 after acquiring an additional 250,000 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Trading Up 1.8%

KROS stock opened at $14.27 on Monday. The stock’s fifty day simple moving average is $13.00 and its two-hundred day simple moving average is $19.14. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The stock has a market cap of $579.58 million, a P/E ratio of -2.74 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $211.25 million for the quarter, compared to analysts’ expectations of $84.62 million. During the same quarter in the previous year, the firm earned ($1.21) earnings per share. As a group, analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 20.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Scotiabank dropped their target price on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating on the stock in a report on Monday, May 12th. Truist Financial dropped their target price on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Wedbush restated a “neutral” rating and issued a $15.00 target price on shares of Keros Therapeutics in a report on Friday. Wells Fargo & Company dropped their target price on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Finally, HC Wainwright dropped their target price on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $37.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.